Literature DB >> 21868485

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.

M H Barnett1, J W Prineas, M E Buckland, J D E Parratt, J D Pollard.   

Abstract

Auto-antibody mediated astrocyte injury is implicated as a primary event in neuromyelitis optica (NMO) by biomarker, post-mortem and experimental studies that differentiate the condition from multiple sclerosis. We describe the clinical, radiological and neuropathological features of a severe cerebral attack in a natalizumab-treated patient with relapsing myelitis and serum aquaporin-4 antibodies. Our findings support autopsy evidence that abrupt astrocyte destruction precedes demyelination in NMO, and emphasize the importance of serological testing in patients with limited disease. Adherence to current NMO diagnostic criteria may delay treatment, or lead to inappropriate therapy with beta-interferon or natalizumab.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21868485     DOI: 10.1177/1352458511421185

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  43 in total

Review 1.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

Review 2.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 3.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  Natalizumab and the development of extensive brain lesions in neuromyelitis optica.

Authors:  Maciej Juryńczyk; Krzysztof Zaleski; Krzysztof Selmaj
Journal:  J Neurol       Date:  2013-05-30       Impact factor: 4.849

5.  [Therapeutic options for autoimmune encephalomyelitis].

Authors:  N Borisow; H Prüss; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 6.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

7.  Treatment of Neuromyelitis Optica: Review and Recommendations.

Authors:  Dorlan J Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jérôme de Seze; Olaf Stuve; Silvia N Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

Review 8.  Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors:  A Salmen; R Gold; A Chan
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 9.  [Ultrahigh field MRI in context of neurological diseases].

Authors:  J Kuchling; T Sinnecker; I Bozin; J Dörr; V I Madai; J Sobesky; T Niendorf; F Paul; J Wuerfel
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

Review 10.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.